Servier, CTI BioPharma in $133.5M Pixuvri Deal

CTI BioPharma entered into an agreement with Servier to develop and commercialize lymphoma drug Pixuvri® (pixantrone).

Partnership Offers Seamless ADC Development and Manufacturing

Fujifilm Diosynth Biotechnologies and Piramal Healthcare in the U.K. are pooling their expertise to offer what they claim is a seamless contract development and manufacturing service for antibody drug conjugates (ADCs).

FDA Gives Abbott a Thumbs-Up for Automated HBV Monitoring Test

Assay can be used with the Abbott m2000 system to understand response to treatment.

Magic Mushrooms Break on Through to Biosynthetic Reality

Enzymatic synthesis of psilocybin, the active ingredient of psychedelic mushrooms, has been detailed

Merck & Co. Expands Pipeline in Cancer, Fibrosis, Autoimmune Diseases by...

Merck & Co. plans to acquire Tilos Therapeutics for up to $773 million, in a deal designed to expand the buyer’s cancer, fibrosis, and autoimmune disease pipelines with therapies targeting the latent TGFβ complex.

Complix’ Series A Financing Reaches €7M for Development of Alphabody Therapeutics

Increased investment round follows recently awarded €1.6M grant from Flanders Government.

Advanced Immunotherapeutic Method Shows Promise against Brain Cancer

Researchers develop novel technique to induce a specific type of cell death in brain cancer cells from mice

EU Backs Consortium Dedicated to Protein Kinase Discovery and Development Services

Eurostars-funded Kinomed Partnership will exploit expertise of KinaseDetect, Iota Pharmaceuticals and SARomics Biostructures.

Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku

Biotie has changed its strategy of focusing on locomotive diseases to fibrotic diseases.

Recently Featured

Stay Connected

556,489FansLike
47,486FollowersFollow
Scroll Up